CAR T-Cell Therapies
Mar 14, 2025
5 Most Promising CAR T-cell Therapies for Multiple Myeloma in Development
The success of CAR-T therapies like Bristol-Myers Squibb/Bluebird bio’s ABECMA and Janssen’s CARVYKTI is reshaping treatment paradigms, challenging traditional options like stem cell transplants and proteasome inhibitors. The multiple myeloma market size in the US is responding rapidly from ~USD 15 billion, with in...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
